15 . 04 .2025
Press release
Galderma launches Sculptra® in China, further fueling its growth into one of the fastest growing aesthetics markets
21 . 03 .2025
Press release
Galderma publishes its 2024 Annual Report and the invitation to its first Annual General Meeting
20 . 03 .2025
Press release
AMWC 2025: Galderma pushes the innovation frontier with updates from its unparalleled portfolio designed to meet the needs of the aesthetic community
17 . 03 .2025
Press release
Galderma’s Differin is helping destigmatize acne care with first in category Roblox experience
14 . 03 .2025
Press release
Galderma successfully placed an inaugural EUR 500 million single tranche Eurobond and new dual tranche CHF 435 million CHF bonds
06 . 03 .2025
Press release
Galderma delivers 2024 record net sales of 4.410 billion USD, up 9.3% year-on-year at constant currency1, and record Core EBITDA of 1.031 billion USD, while preparing to accelerate its growth trajectory into 2025 and beyond
03 . 03 .2025
Press release
AAD 2025: Galderma to present extensive updates from across its dermatology portfolio, demonstrating its category leadership and strong momentum
18 . 02 .2025
Press release
Galderma’s Nemluvio® (nemolizumab) granted marketing authorization in the United Kingdom and Switzerland for moderate-to-severe atopic dermatitis and prurigo nodularis